cGAS-STING signalling in cancer: striking a balance with chromosomal instability.
Beernaert B. and Parkes EE., (2023), Biochem Soc Trans
A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.
Fletcher CE. et al, (2022), Mol Cancer, 21
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers.
van Vugt MATM. and Parkes EE., (2022), Trends Cancer, 8, 174 - 189
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer.
Parkes EE. et al, (2022), Br J Cancer, 126, 247 - 258
The tumor microenvironment and immune responses in prostate cancer patients.
Kwon JTW. et al, (2021), Endocr Relat Cancer, 28, T95 - T107
Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors.
Harrington K. et al, (2021), CANCER RESEARCH, 81
The clinical and molecular significance associated with STING signaling in breast cancer.
Parkes EE. et al, (2021), NPJ Breast Cancer, 7
Development of Immunotherapy Combination Strategies in Cancer.
Yap TA. et al, (2021), Cancer Discov, 11, 1368 - 1397
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
Li J. et al, (2021), Cancer Discov, 11, 1212 - 1227
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Willenbrock F. et al, (2021), Br J Cancer, 124, 581 - 586
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
Philippou Y. et al, (2020), Br J Cancer, 123, 1089 - 1100
The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer
Parkes EE. et al, (2020)
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Sharma P. et al, (2019), Journal of Clinical Oncology, 37, 3484 - 3492
Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study
McCain RS. et al, (2019), Cancer Causes & Control, 31, 1 - 11
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Turkington RC. et al, (2019), Gut, 68, 1918 - 1927
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy
Gilmore E. et al, (2019), JOURNAL OF ONCOLOGY, 2019
Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application
Lightbody G. et al, (2019), BRIEFINGS IN BIOINFORMATICS, 20, 1795 - 1811
Topoisomerase II inhibitors induce cGAS-STING dependent inflammation resulting in cytokine induction and immune checkpoint activation
Wilkinson RDA. et al, (2019)
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
Humphries MP. et al, (2018), Journal of Oncology, 2018, 1 - 14
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
Parkes EE. et al, (2016), Journal of the National Cancer Institute, 109, djw199 - djw199